Frederick BIO Roundtable Showcases State and County Strengths

Published on :

Located in the northern part of Maryland along the I-270 Technology Corridor, Frederick County is home to more than  80 bioscience companies. With proximity to Fort Detrick, home to the Frederick National Laboratory for Cancer Research, the county boasts a powerful environment of life sciences intellectual prowess.

Maryland Life Science Companies Share Hopes for Annual BIO Convention

Published on :

Over a period of four days, life sciences companies from across the globe will descend on San Diego for the annual Biotechnology Innovation Organization (BIO) meeting. Multiple companies from Maryland, as well as the Department of Commerce, will be among them, showcasing the strength of the BioHealth Capital Region.

Biosimilars Market is Fertile Ground for Impact Investors

Published on :

An impact investor can be an individual or investment fund that has co-equal primary goals: to make money and foment positive social change that can last. In some ways, impact investors are “social VCs”—they fund projects and companies that can create positive, measurable impact for the greater good of humanity. Unlike traditional VC investment strategies that tend to take a high risk, high reward approach, impact investing generally focuses on lower risk, more modest or conservative financial investments that yield the most possible good for people and communities.

Despite Strong 2021 Performance Headwinds Remain for Biosimilars Uptake

Published on :

Biosimilars, also known as follow-on biologics, continued to capture greater market share and foment stronger competition with reference or brand name drugs in 2021. Increasing the number of biosimilars in the market and amplifying uptake by payers, family medical practices and pharmacies could be a gamechanger for patients and a healthcare system trying to reduce the cost of life-changing medicines.

In Conversation: David Vanik, Ph.D., Partner at McBee Moore & Vanik IP

Headshot of David Vanik of MMVIP
Published on :

Since the days of working on his Ph.D. in protein science, David Vanik has had an interest in intellectual property and patent law. As Vanik closed in on completing his doctoral research, he began to look at IP within the area of biotechnology.

Theradaptive Wins Additional FDA Breakthrough Designation for Spinal Fusion

Published on :

Theradaptive Wins Additional FDA Breakthrough Designation for Spinal Fusion Feb 15, 2022, 14:31 ET Theradaptive  FREDERICK, Md. and BOSTON, Feb. 15, 2022 /PRNewswire/ — Theradaptive, a privately held biopharmaceutical company pioneering a new class of [….]

Help Wanted in Biomanufacturing: The need for more training programs for workers grows

Published on :

Many community colleges are now offering intense boot camps that last weeks instead of years, she says. Montgomery College and Frederick Community College, both in Maryland, launched weeks-long biotech boot camps in 2021 and 2022, respectively.
Graduates usually leave with a certificate and the laboratory skills that employers are looking for, such as moving cells without contaminating them and donning gear needed to work in a sterile environment.

Three Local Biotechs Focused on Improving Military Performance and Medical Care

Logos for ARMR Systems, Theradaptive, and Juxtopia overlayed on an image of soldiers' legs
Published on :

Biotech companies focused on developing biodefense products and measures are well known throughout the BioHealth Capital Region (BHCR). Companies like BioFactura, which is developing a smallpox therapeutic, and Emergent BioSolutions, which is advancing an anthrax vaccine, are two regional organizations BioBuzz has covered extensively. 

Infectious Disease Focused Zalgen Labs Opens New HQ in Frederick, Eyes Clinical Trial for Lassa Fever Therapeutic

Zalgen logo overlaying a photo of three laboratory workers in PPE
Published on :

Zalgen Labs, which until late December been housed at the Germantown Innovation Center for the past eight years, is focused on developing diagnostics and therapeutics for infectious emerging viral threats that have become endemic in the far corners of the world, including diseases such as Lassa fever, Ebola and other hemorrhagic diseases.